Lentiviruses (more commonly used) vs. gammaretroviruses (old technology)

  • Similarities
    • Both retroviruses
    • Insert DNA randomly into host genome using viral integrase enzyme, creating permanent genetic changes (cell passes modifications down to daughter cells)
  • Differences
    • Lentivirus (derived from HIV) - used for frequently today (2024)
      • can infect both dividing and non-dividing cells
      • DNA is actively transported into host’s nucleus
      • has a more complex viral genome
    • Gammaretrovirus - older technology, was only used first bc it was better understood vs. lentivirus (HIV) in the early days and had a simpler genome
      • only infects dividing cells
      • needs nuclear membrane to breakdown
      • simpler viral genome

Applications

  • Lentiviral vectors are good when you need:
    • Permanent gene integration
    • Stable, long-term expression
    • High efficiency delivery
  • Main drawback: random integration
    • cannot control where CAR genes integrate (pseudo-random integration)
    • risk of insertional mutagenesis (randomly-inserted genes can accidentally activate oncogenes, disrupt tumor suppressor genes)
    • variable CAR expression levels: if viral vector inserts gene in
      • highly transcriptionally active, open chromatin regions high CAR expression
      • not very transcriptionally active chromatin region low CAR expression
  • Real-world example of lentiviral vectors in action:
    • FDA-approved CAR-T products (e.g. Kymriah, Yescarta)
    • Research tool for gene delivery
  • Gammaretroviruses not used anymore bc they can only infect dividing cells

Transduction process

  1. Virus binds to cell surface
  2. Enters cell through membrane fusion
  3. Viral RNA released into cytoplasm
  4. RNA is reverse transcribed to DNA (via host’s reverse transcriptase)
  5. viral cDNA enters nucleus and integrates into host’s genome, using viral integrase enzyme

Used in CAR T cell production

  • Gene of interest (e.g. CAR) packaged in viral genome
  • Viral particles are engineered to be non-pathogenic while maintaining the ability to deliver and integrate genes
  • Currently (2024) used in FDA-approved CAR-T products